Rodriguez Duran M, OKeefe G
Front Ophthalmol (Lausanne). 2024; 3:1257068.
PMID: 38983096
PMC: 11182217.
DOI: 10.3389/fopht.2023.1257068.
Liu D, Saikam V, Skrada K, Merlin D, Iyer S
Med Res Rev. 2022; 42(5):1856-1887.
PMID: 35603998
PMC: 10321231.
DOI: 10.1002/med.21893.
Kim J, Cheon J
Intest Res. 2020; 18(3):249-264.
PMID: 32295331
PMC: 7385581.
DOI: 10.5217/ir.2019.00128.
Vavricka S, Schoepfer A, Scharl M, Lakatos P, Navarini A, Rogler G
Inflamm Bowel Dis. 2015; 21(8):1982-92.
PMID: 26154136
PMC: 4511685.
DOI: 10.1097/MIB.0000000000000392.
Schwartzman S, Schwartzman M
Clin Rev Allergy Immunol. 2014; 49(3):307-16.
PMID: 25431348
DOI: 10.1007/s12016-014-8455-6.
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
Pasadhika S, Rosenbaum J
Biologics. 2014; 8:67-81.
PMID: 24600203
PMC: 3933243.
DOI: 10.2147/BTT.S41477.
Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.
Trikudanathan G, Venkatesh P, Navaneethan U
Drugs. 2012; 72(18):2333-49.
PMID: 23181971
DOI: 10.2165/11638120-000000000-00000.
Necrotizing keratitis after laser refractive surgery in patients with inactive inflammatory bowel disease.
Aman-Ullah M, Gimbel H, Purba M, van Westenbrugge J
Case Rep Ophthalmol. 2012; 3(1):54-60.
PMID: 22611369
PMC: 3355644.
DOI: 10.1159/000336567.
Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?.
Veloso F
World J Gastroenterol. 2011; 17(22):2702-7.
PMID: 21734777
PMC: 3122258.
DOI: 10.3748/wjg.v17.i22.2702.
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.
Heiligenhaus A, Thurau S, Hennig M, Grajewski R, Wildner G
Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1531-51.
PMID: 20737162
DOI: 10.1007/s00417-010-1485-8.
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.
Sadowski D, Bernstein C, Bitton A, Croitoru K, Fedorak R, Griffiths A
Can J Gastroenterol. 2009; 23(3):185-202.
PMID: 19319383
PMC: 2694654.
DOI: 10.1155/2009/201430.
Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit.
Theodossiadis P, Liarakos V, Sfikakis P, Charonis A, Agrogiannis G, Kavantzas N
Graefes Arch Clin Exp Ophthalmol. 2008; 247(2):273-81.
PMID: 18982345
DOI: 10.1007/s00417-008-0967-4.
Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Siemanowski B, Regueiro M
Curr Treat Options Gastroenterol. 2007; 10(3):178-84.
PMID: 17547856
DOI: 10.1007/s11938-007-0011-5.
Adalimumab in the therapy of uveitis in childhood.
Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D
Br J Ophthalmol. 2006; 91(3):319-24.
PMID: 17035274
PMC: 1857691.
DOI: 10.1136/bjo.2006.103721.
Extraintestinal manifestations and complications in inflammatory bowel diseases.
Rothfuss K, Stange E, Herrlinger K
World J Gastroenterol. 2006; 12(30):4819-31.
PMID: 16937463
PMC: 4087615.
DOI: 10.3748/wjg.v12.i30.4819.
Conventional therapy for Crohn's disease.
Buning C, Lochs H
World J Gastroenterol. 2006; 12(30):4794-806.
PMID: 16937460
PMC: 4087612.
DOI: 10.3748/wjg.v12.i30.4794.
Extraintestinal manifestations in inflammatory bowel disease.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G
World J Gastroenterol. 2006; 11(46):7227-36.
PMID: 16437620
PMC: 4725142.
DOI: 10.3748/wjg.v11.i46.7227.
Infliximab: Use in Inflammatory Bowel Disease.
Travassos W, Cheifetz A
Curr Treat Options Gastroenterol. 2005; 8(3):187-196.
PMID: 15913508
DOI: 10.1007/s11938-005-0011-2.
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
Braun J, Sieper J
Arthritis Res. 2002; 4(5):307-21.
PMID: 12223105
PMC: 128942.
DOI: 10.1186/ar592.
